 |
|
|
| |
Senolytics dasatinib and quercetin reduce fibrosis in metabolic dysfunction-associated steatohepatitis: The Truth Study
|
| |
| |
comments from audience after presentation raised doubts - seeing such large improvements in such short time of therapy, and safety concerns. Dr Koning pressured questioners and said more can be learned from phase 3 trial.
|
| |
|
|
|
|
|
